about
Metabolic Issues With Atypical Antipsychotics in Primary Care: Dispelling the MythsMedication-induced diabetes mellitus.A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data.Antipsychotic medication during pregnancy and lactation in women with schizophrenia: evaluating the risk.Understanding antipsychotic "atypicality": a clinical and pharmacological moving targetBehavioural management of antipsychotic-induced weight gain: a review.The assessment and management of antipsychotic-associated metabolic disturbances from a psychiatric perspective.Atypical antipsychotics and diabetes mellitus.Pharmacological treatment strategies for schizophrenia.Emerging treatments for bipolar disorder: safety and adverse effect profiles.Life-threatening hyperglycemia and acidosis related to olanzapine: a case report and review of the literature.A UK audit of screening for the metabolic side effects of antipsychotics in community patients.Drug safety evaluation of olanzapine pamoate.The impact of weight gain associated with atypical antipsychotic use in schizophrenia.Cardiovascular Disease in Clozapine-Treated Patients: Evidence, Mechanisms and Management.Olanzapine impairs glycogen synthesis and insulin signaling in L6 skeletal muscle cells.New-onset seizure associated with quetiapine and olanzapine.The prevalence of the metabolic syndrome in patients with schizoaffective disorder--bipolar subtype.High-dose olanzapine-induced improvement of preexisting type 2 diabetes mellitus in schizophrenic patients.Diabetic keto-acidotic (DKA) coma following olanzapine initiation in a previously euglycaemic woman and successful continued therapy with olanzapine.Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome.An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia.Alterations of glucose metabolism during treatment with clozapine or amisulpride: results from a prospective 16-week study.The safety of clozapine in the elderly.Developing a service to monitor and improve physical health in people with serious mental illness.
P2860
Q24596954-D72BE67D-DD49-40C9-A158-A98E556EAE96Q30276191-1D8F34EA-0849-432F-B118-C16A1105983AQ30667146-59FB516A-9B4E-4F11-850E-0AFF93462C02Q35054800-82A9627C-263E-4CFC-BE91-E5A46658333CQ35200831-2A9E7A75-A677-4D76-8C27-30BE6171D52FQ35212362-90C94294-03DB-492F-BC8B-8642614842FEQ35752734-80EF6849-734B-4243-A7D8-7C978C023CD7Q35793345-45CCDC4B-1FC0-476E-B499-07072D4D604DQ36107179-C9696A96-ADA5-4FCA-BBDB-0DD7BFE3801DQ36364980-28F4F1FD-7A02-430F-9F0E-E811C008F97CQ36720733-1CBDBBEC-6673-4E64-BDC1-706097CBFB5EQ37427104-5FC1CEDD-1B5A-4100-B223-622269D07CA0Q38136262-03EECB24-B711-47ED-B018-DF4CCD98025EQ38777526-20BDFD8B-BEC9-4C42-8CD4-BB19B1D8D9FCQ40082921-51CEC9DA-4F0B-4691-970D-2E4373EEF497Q40380108-D21BFDD3-E5C3-4FAE-8AF6-AC4DC2BD3AADQ43918023-3DA5D6B6-2EC4-478C-A341-7BC20ED34BBDQ44207549-3FE5BD5B-1D06-4F6B-A3FC-3E991A5EB775Q44902733-262B0027-EC98-4E98-84DB-724CE158F164Q45053026-721E516B-45AB-4026-887C-74B1A68EFDD0Q45212721-975D8B41-B5E2-48B2-8F29-73A0C4EA6537Q46901298-BF03FE02-F841-4A23-91AD-D172765D247FQ51487515-AC276776-BB4C-44CF-A2AF-373D37997E56Q51886953-2CDE0C99-1000-4D96-BB29-B60EC6D744B0Q51925964-644095F7-38E3-4CF6-A79C-889A8DF903FE
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Atypical antipsychotics and hyperglycaemia.
@ast
Atypical antipsychotics and hyperglycaemia.
@en
type
label
Atypical antipsychotics and hyperglycaemia.
@ast
Atypical antipsychotics and hyperglycaemia.
@en
prefLabel
Atypical antipsychotics and hyperglycaemia.
@ast
Atypical antipsychotics and hyperglycaemia.
@en
P1476
Atypical antipsychotics and hyperglycaemia.
@en
P356
10.1097/00004850-200103000-00001
P577
2001-03-01T00:00:00Z